Proteintech acquires ChromoTek

By The Science Advisory Board staff writers

October 20, 2020 -- Proteintech, a German-based producer of antibodies, proteins, and immunoassays, has acquired ChromoTek, a manufacturer of camelid single-domain antibodies (aka nanobodies).

ChromoTek produces the nanobodies with high-performance recombinant reagents. Combined with Proteintech, the companies will address growing opportunities in single-cell analysis, super-resolution imaging, and multiplex assays.

Proteintech has a large portfolio of self-manufactured antibodies covering two-thirds of the human proteome. The company also offers cytokines, growth factors, and other human-expressed proteins.

Financial details were not disclosed.

Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2.
Genetically engineered probiotics successfully deliver immunotherapies
A new technology enables genetically engineered probiotic bacteria to be used as an efficacious, stable, and safe platform to deliver immunotherapies...

Copyright © 2020

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter